ClearBridge Investments
ITCI

ClearBridge Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

ClearBridge Investments’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,686,384
Closed -$141M – 753
2024
Q4 		$141M Sell
1,686,384
-43,345
-3% -$3.56M 0.11% 181
2024
Q3 		$127M Buy
1,729,729
+8,119
+0.5% +$610K 0.1% 200
2024
Q2 		$118M Sell
1,721,610
-22,941
-1% -$1.59M 0.1% 201
2024
Q1 		$121M Buy
1,744,551
+191,416
+12% +$13.2M 0.1% 225
2023
Q4 		$111M Buy
1,553,135
+149,534
+11% +$8.6M 0.1% 223
2023
Q3 		$73.1M Sell
1,403,601
-10,144
-0.7% -$591K 0.07% 254
2023
Q2 		$89.5M Buy
1,413,745
+363,870
+35% +$22.7M 0.08% 241
2023
Q1 		$56.9M Buy
1,049,875
+390,493
+59% +$18.9M 0.05% 295
2022
Q4 		$34.9M Buy
659,382
+8,099
+1% +$406K 0.03% 375
2022
Q3 		$30.3M Buy
651,283
+446,112
+217% +$23.3M 0.03% 379
2022
Q2 		$11.7M Sell
205,171
-35,257
-15% -$2M 0.01% 518
2022
Q1 		$14.7M Sell
240,428
-90,742
-27% -$4.71M 0.01% 522
2021
Q4 		$17.3M Sell
331,170
-102,148
-24% -$4.29M 0.01% 502
2021
Q3 		$16.2M Sell
433,318
-40,075
-8% -$1.39M 0.01% 526
2021
Q2 		$19.3M Sell
473,393
-2,119
-0.4% -$78.3K 0.01% 519
2021
Q1 		$16.1M Sell
475,512
-146,233
-24% -$5.07M 0.01% 521
2020
Q4 		$19.8M Sell
621,745
-24,776
-4% -$651K 0.02% 470
2020
Q3 		$16.6M Buy
646,521
+20,379
+3% +$465K 0.01% 457
2020
Q2 		$16.1M Buy
626,142
+114,764
+22% +$2.32M 0.01% 443
2020
Q1 		$7.86M Buy
511,378
+193,769
+61% +$4.21M 0.01% 508
2019
Q4 		$10.5M Sell
317,609
-467,529
-60% -$5.61M 0.01% 542
2019
Q3 		$5.87M Buy
+785,138
New +$7.53M 0.01% 577

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

ClearBridge Investments's ITCI Position: Q1 2025 in Review

ClearBridge Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 1,686,384 shares — an estimated $141M sold.

ClearBridge Investments first reported a position in ITCI in Q3 2019 and held it in 22 quarters. The position peaked at $141M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • ClearBridge Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • ClearBridge Investments sold 1,686,384 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $141M.
  • ClearBridge Investments first reported a position in Intra-Cellular Therapies Inc. in Q3 2019 and held it in 22 quarters.
  • ClearBridge Investments's Intra-Cellular Therapies Inc. position peaked at $141M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on ClearBridge Investments's 13F filing for Q1 2025, filed 13 May 2025.